Other coagulation defects
Notes: Partial quantitative deficiency of von Willebrand factor ; Type 1C von Willebrand disease ; Qualitative defects of von Willebrand factor ; Qualitative defects of von Willebrand factor with decreased platelet adhesion and selective deficiency of high-molecular-weight multimers ; Qualitative defects of von Willebrand factor with high-molecular-weight von Willebrand factor loss ; Qualitative defects of von Willebrand factor with hyper-adhesive forms ; Qualitative defects of von Willebrand factor with increased affinity for platelet glycoprotein lb ; Qualitative defects of von Willebrand factor with defective platelet adhesion with a normal size distribution of von Willebrand factor multimers ; Qualitative defects of von Willebrand factor with defective von Willebrand factor to factor VIII binding ; Qualitative defects of von Willebrand factor with markedly decreased affinity for factor VIII ; Qualitative defect in von Willebrand factor function, with no further subtyping ; (Near) complete absence of von Willebrand factor ; Total quantitative deficiency of von Willebrand factor ; Acquired von Willebrand syndrome ; Platelet-type von Willebrand disease ; Pseudo-von Willebrand disease ; Hemophilia C ; Plasma thromboplastin antecedent [PTA] deficiency ; Rosenthal’s disease ; AC globulin deficiency ; Congenital afibrinogenemia ; Deficiency of factor I [fibrinogen] ; Deficiency of factor II [prothrombin] ; Deficiency of factor V [labile] ; Deficiency of factor VII [stable] ; Deficiency of factor X [Stuart-Prower] ; Deficiency of factor XII [Hageman] ; Deficiency of factor XIII [fibrin stabilizing] ; Dysfibrinogenemia (congenital) ; Hypoproconvertinemia ; Owren’s disease ; Proaccelerin deficiency ; Autoimmune hemophilia ; Autoimmune inhibitors to clotting factors ; Secondary hemophilia ; Lupus anticoagulant (LAC) with hemorrhagic disorder ; Systemic lupus erythematosus [SLE] inhibitor with hemorrhagic disorder ; Antithromboplastinemia ; Antithromboplastinogenemia ; Hemorrhagic disorder due to intrinsic increase in antithrombin ; Hemorrhagic disorder due to intrinsic increase in anti-VIIIa ; Hemorrhagic disorder due to intrinsic increase in anti-IXa ; Hemorrhagic disorder due to intrinsic increase in anti-XIa ; Drug-induced hemorrhagic disorder ; Hemorrhagic disorder due to increase in anti-IIa ; Hemorrhagic disorder due to increase in anti-Xa ; Hyperheparinemia ; Deficiency of coagulation factor due to liver disease ; Deficiency of coagulation factor due to vitamin K deficiency ; Primary hypercoagulable states ; Factor V Leiden mutation ; Antithrombin III deficiency ; Hypercoagulable state NOS ; Primary hypercoagulable state NEC ; Primary thrombophilia NEC ; Protein C deficiency ; Protein S deficiency ; Thrombophilia NOS ; Other hypercoagulable states ; Anticardiolipin syndrome ; Antiphospholipid antibody syndrome ; Lupus anticoagulant ; Presence of systemic lupus erythematosus [SLE] inhibitor ; Hypercoagulable states NEC ; Secondary hypercoagulable state NOS ; code for adverse effect, if applicable, to identify drug (T45.515, T45.525) ; abnormal coagulation profile NOS (R79.1) ; capillary fragility (hereditary) (D69.8) ; factor VIII deficiency NOS (D66) ; factor VIII deficiency with functional defect (D66) ; antiphospholipid antibody, finding without diagnosis (R76.0) ; antiphospholipid antibody syndrome (D68.61) ; antiphospholipid antibody with hypercoagulable state (D68.61) ; lupus anticoagulant (LAC) finding without diagnosis (R76.0) ; lupus anticoagulant (LAC) with hypercoagulable state (D68.62) ; systemic lupus erythematosus [SLE] inhibitor finding without diagnosis (R76.0) ; systemic lupus erythematosus [SLE] inhibitor with hypercoagulable state (D68.62) ; vitamin K deficiency of newborn (P53) ; antiphospholipid syndrome (D68.61) ; lupus anticoagulant (D68.62) ; secondary activated protein C resistance (D68.69) ; secondary antiphospholipid antibody syndrome (D68.69) ; secondary lupus anticoagulant with hypercoagulable state (D68.69) ; secondary systemic lupus erythematosus [SLE] inhibitor with hypercoagulable state (D68.69) ; systemic lupus erythematosus [SLE] inhibitor finding without diagnosis (R76.0) ; systemic lupus erythematosus [SLE] inhibitor with hemorrhagic disorder (D68.312) ; thrombotic thrombocytopenic purpura (M31.19) ; diffuse or disseminated intravascular coagulation [DIC] (D65) ; heparin induced thrombocytopenia (HIT) (D75.82-) ; hyperhomocysteinemia (E72.11) ; anti-phospholipid antibody, finding without diagnosis (R76.0) ; anti-phospholipid antibody with hemorrhagic disorder (D68.312) ; lupus anticoagulant syndrome (D68.62) ; anticardiolipin syndrome (D68.61) ; antiphospholipid syndrome (D68.61) ; lupus anticoagulant (LAC) finding without diagnosis (R76.0) ; lupus anticoagulant (LAC) with hemorrhagic disorder (D68.312) ; hemorrhagic disease of newborn (P53) ; coagulation defects complicating abortion or ectopic or molar pregnancy (O00-O07, O08.1) ; coagulation defects complicating pregnancy, childbirth and the puerperium (O45.0, O46.0, O67.0, O72.3)